Search the GHTC website

Global health R&D delivers for Kentucky

US government investment in global health R&D has delivered

Amount
$15 million
to Kentucky research institutions
Jobs
150+ new jobs
for Kentucky
Kentucky's top USG-funded global health R&D institutions

Kentucky's top USG-funded global health R&D institutions

University of Louisville
$12.4 million
University of Kentucky
$2 million
Owensboro Medical Health System, Inc.
$494 thousand
Kentucky industry in global health R&D

Kentucky industry in global health R&D

Amgen
Location(s): Louisville
ArtemiFlow
Location(s): Lexington
Kentucky BioProcessing
Location(s): Owensboro
MosquitoMate
Location(s): Lexington
Vindico NanoBioTechnology
Location(s): Lexington

Kentucky's top areas of global health R&D by USG funding

74.9%
HIV/AIDS
7.3%
Tuberculosis
6.2%
Salmonella infections
6.3%
Neglected tropical diseases
Helminths
5.2%
Other
Ebola/viral hemorrhagic fevers
Malaria
Global health R&D at work in Kentucky

Researchers at the University of Tennessee and University of Louisville have discovered that a person’s gut microbes can impact the severity of malaria infection. Malaria is a mosquito-borne disease that infects more than 200 million people each year, killing almost half a million, mostly young children. There is currently no completely effective vaccine, and the parasite is growing resistant to available drug therapies. The researchers discovered that the degree of harm caused by malaria is not only a function of the parasite but is also influenced by microbes in the infected organism. This discovery opens new doors for investigation and could lead to new treatments for malaria or new approaches to improve the effectiveness of existing methods.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Rocky Prajapati